Fundamental Analysis of HERON THERAPEUTICS INC(NASDAQ:HRTX) stock

Fundamental Rating

Overall HRTX gets a fundamental rating of 2 out of 10. We evaluated HRTX against 588 industry peers in the Biotechnology industry. HRTX has a bad profitability rating. Also its financial health evaluation is rather negative. HRTX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

HRTX had negative earnings in the past year.

In the past year HRTX has reported a negative cash flow from operations.

HRTX had negative earnings in each of the past 5 years.

In the past 5 years HRTX always reported negative operating cash flow.

1.2 Ratios

HRTX's Return On Assets of -49.69% is in line compared to the rest of the industry. HRTX outperforms 50.34% of its industry peers.

		Industry Rank	Sector Rank
ROA	-49.69%
ROE	N/A
ROIC	N/A

ROA(3y)-64.8%

ROA(5y)-59.72%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

HRTX has a Gross Margin of 48.75%. This is amongst the best in the industry. HRTX outperforms 80.03% of its industry peers.

HRTX's Gross Margin has declined in the last couple of years.

HRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	48.75%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.24%

GM growth 5Y-5.45%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for HRTX has been increased compared to 1 year ago.

Compared to 5 years ago, HRTX has more shares outstanding

The debt/assets ratio for HRTX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -11.66, we must say that HRTX is in the distress zone and has some risk of bankruptcy.

HRTX has a Altman-Z score of -11.66. This is in the lower half of the industry: HRTX underperforms 79.69% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-11.66

ROIC/WACCN/A

WACC6.98%

2.3 Liquidity

A Current Ratio of 2.37 indicates that HRTX has no problem at all paying its short term obligations.

With a Current ratio value of 2.37, HRTX is not doing good in the industry: 74.57% of the companies in the same industry are doing better.

A Quick Ratio of 1.84 indicates that HRTX should not have too much problems paying its short term obligations.

The Quick ratio of HRTX (1.84) is worse than 75.94% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.37
Quick Ratio	1.84

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.29% over the past year.

Looking at the last year, HRTX shows a quite strong growth in Revenue. The Revenue has grown by 17.98% in the last year.

Measured over the past years, HRTX shows a quite strong growth in Revenue. The Revenue has been growing by 10.39% on average per year.

EPS 1Y (TTM)50.29%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q58.82%

Revenue 1Y (TTM)17.98%

Revenue growth 3Y12.76%

Revenue growth 5Y10.39%

Revenue growth Q2Q14%

3.2 Future

The Earnings Per Share is expected to grow by 22.01% on average over the next years. This is a very strong growth

Based on estimates for the next years, HRTX will show a very strong growth in Revenue. The Revenue will grow by 21.12% on average per year.

EPS Next Y47.02%

EPS Next 2Y25.42%

EPS Next 3Y28.97%

EPS Next 5Y22.01%

Revenue Next Year17.89%

Revenue Next 2Y19.07%

Revenue Next 3Y20.15%

Revenue Next 5Y21.12%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.

Also next year HRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as HRTX's earnings are expected to grow with 28.97% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.42%

EPS Next 3Y28.97%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for HRTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HERON THERAPEUTICS INC

NASDAQ:HRTX (5/1/2024, 12:28:58 PM)

2.345

+0.03 (+1.08%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap352.52M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.69%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	48.75%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.57

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.37
Quick Ratio	1.84
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)50.29%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y47.02%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)17.98%

Revenue growth 3Y12.76%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

HERON THERAPEUTICS INC (HRTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens